Core Viewpoint - Avis Budget Group, Inc. is facing allegations of issuing materially false and misleading statements regarding its fleet rotation plan, which has led to significant financial implications for the company [1]. Group 1: Allegations and Financial Impact - The complaint alleges that Avis Budget implemented a plan to significantly accelerate its fleet rotation in Q4 2024 [1]. - This acceleration shortened the useful life of the majority of the company's vehicles in the Americas segment, reducing their recoverable value [1]. - As a result, Avis Budget is expected to recognize billions of dollars in impairment charges and incur substantial losses [1]. - The aforementioned actions are likely to have a significant negative impact on the company's financial results [1]. - Consequently, the financial and business prospects of Avis Budget were overstated, making the defendants' public statements materially false and misleading [1]. Group 2: Class Action Details - Shareholders who purchased shares of Avis Budget during the class period from February 16, 2024, to February 10, 2025, are encouraged to register for the class action [2]. - The deadline for shareholders to seek lead plaintiff status is June 24, 2025 [2]. - There is no cost or obligation for shareholders to participate in this case [2].

Core Viewpoint - NeuroPace, Inc. is under investigation for potential securities fraud and unlawful business practices following disappointing results from a clinical study [1][3]. Group 1: Company Performance - On May 27, 2025, NeuroPace announced the preliminary one-year results of the NAUTILUS study, which evaluated the safety and effectiveness of the RNS System for treating drug-resistant idiopathic generalized epilepsy (IGE) [3]. - The study did not achieve statistical significance for its primary effectiveness endpoint, which aimed to demonstrate a longer time to a second generalized tonic-clonic seizure in the active stimulation group compared to the sham stimulation group [3]. - Following the announcement, NeuroPace's stock price dropped by $5.02 per share, or 28.39%, closing at $12.66 per share on the same day [3]. Group 2: Legal Investigation - Pomerantz LLP is investigating claims on behalf of NeuroPace investors regarding possible securities fraud or other unlawful business practices by the company and its officers and/or directors [1]. - Investors are encouraged to contact Pomerantz LLP for more information about the investigation and potential class action [1].

Core Viewpoint - Pomerantz LLP is investigating claims on behalf of investors of Semler Scientific Inc. regarding potential securities fraud or unlawful business practices by the company and its officers or directors [1]. Group 1: Company Disclosure - On February 28, 2025, Semler filed its annual report for 2024, indicating a risk of a complaint from the U.S. Department of Justice (DOJ) related to a civil False Claims Act lawsuit [3]. - Semler disclosed receiving an initial civil investigative demand from the DOJ in July 2017 concerning reimbursement claims for its QuantaFlo device [3]. - The company participated in unsuccessful settlement discussions with the DOJ in February 2025 [3]. Group 2: Market Reaction - Following the news of the DOJ investigation, Semler's stock price dropped by $4.03 per share, or 9.4%, closing at $38.89 per share on March 3, 2025 [4].

Core Viewpoint - A securities class action lawsuit has been filed against Elevance Health, Inc. for alleged misrepresentation of financial conditions during the Class Period from April 18, 2024, to October 16, 2024 [1][2]. Company Overview - Elevance Health, Inc. is a healthcare company based in Indianapolis, providing health insurance plans and administering Medicaid benefits for eligible beneficiaries [3]. Allegations and Financial Impact - The lawsuit claims that Elevance misled investors about its monitoring of cost trends related to the Medicaid "redetermination" process, assuring them that premium rates were sufficient despite rising Medicaid expenses [4]. - The redetermination process led to a significant increase in the utilization of Medicaid members, as healthier members were being removed from the program, which was not reflected in Elevance's financial guidance or rate negotiations [5]. - On July 17, 2024, Elevance disclosed an expected increase in Medicaid utilization, resulting in a stock price drop of $32.21 per share, or 5.8%, closing at $520.93 [6]. - On October 17, 2024, Elevance reported Q3 2024 earnings, missing EPS expectations by $1.33, or 13.7%, and lowered its EPS guidance for 2024 from $37.20 to $33.00, or 11.3%, due to ongoing Medicaid issues [7]. - Following this announcement, Elevance's stock price fell by $52.61 per share, or 10.6%, closing at $444.35 [8].

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving Redwire Corporation and its officers or directors [1]. Financial Performance - Redwire reported Q1 2025 revenue of $61.4 million, which missed consensus estimates by $13.14 million and marked a 30.1% decline year-over-year [3]. - The company attributed the revenue decline to delays in U.S. government contract awards, linked to leadership transitions at agencies such as NASA and the Space Development Agency, as well as changing budget priorities under the Trump administration [3]. Stock Market Reaction - Following the financial results announcement, Redwire's stock price decreased by $0.75 per share, or 6.63%, closing at $10.56 per share on May 12, 2025 [4].

Core Viewpoint - Pomerantz LLP is investigating claims of potential securities fraud and unlawful business practices involving SelectQuote, Inc. and its officers or directors [1] Group 1: Legal Issues - The U.S. Department of Justice filed a False Claims Act complaint against SelectQuote and other health insurance companies, alleging that from 2016 to 2021, they paid hundreds of millions of dollars in illegal kickbacks to brokers for enrollments in Medicare Advantage plans [3] - Following the DOJ's announcement, SelectQuote's stock price dropped by $0.61, or 19.24%, closing at $2.56 per share on May 1, 2025 [3] Group 2: Company Background - Pomerantz LLP is recognized as a leading firm in corporate, securities, and antitrust class litigation, with a history of over 85 years in fighting for victims of securities fraud and corporate misconduct [4]

NEW YORK, May 27, 2025 /PRNewswire/ --Why: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of common stock of DoubleVerify Holdings, Inc. (NYSE: DV) between November 10, 2023 and February 27, 2025, both dates inclusive (the "Class Period"). If you wish to serve as lead plaintiff, you must move the Court no later than July 21, 2025.So What: If you purchased DoubleVerify common stock during the Class Period you may be entitled to compen ...

LOS ANGELES, May 27, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against SoundHound AI, Inc. ("SoundHound" or "the Company") (NASDAQ: SOUN) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Investors who purchased the Company's securities between May 10, 2024 and March 3, 2025, inclusive (the "Class Period"), ar ...

Core Viewpoint - A lawsuit has been filed against BigBear.ai Holdings, Inc. and certain senior executives for potential violations of federal securities laws, specifically under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 [1][2]. Group 1: Company Overview - BigBear.ai is an AI-driven technology solutions company that focuses on operationalizing AI for national security, supply chain management, and digital identity and biometrics solutions [3]. - The company went public through a SPAC transaction, merging with GigCapital4 Merger Sub Corporation and subsequently with GigCapital4, Inc. [4]. Group 2: Financial Misstatements - BigBear.ai issued $200 million of unsecured convertible notes with a maturity date of December 15, 2026, but improperly accounted for these notes, leading to misstatements in previous financial statements [4]. - On March 18, 2025, BigBear.ai announced a delay in filing its 2024 10-K, stating that certain financial statements since fiscal year 2021 should no longer be relied upon and would be restated, resulting in a stock price decline of approximately 15% [5]. - Following the filing of the restated 2024 10-K on March 25, 2025, which disclosed a material weakness in internal control over financial reporting, the stock price fell by about 9% [6].

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud and unlawful business practices involving Redwire Corporation and its executives [1] Financial Performance - Redwire reported Q1 2025 revenue of $61.4 million, missing consensus estimates by $13.14 million, which represents a 30.1% year-over-year decline [2] - The company attributed the revenue decline to delays in U.S. government contract awards due to leadership transitions at agencies like NASA and the Space Development Agency, as well as shifting budget priorities under the Trump administration [2] Stock Market Reaction - Following the financial results announcement, Redwire's stock price fell by $0.75 per share, or 6.63%, closing at $10.56 per share on May 12, 2025 [3]